RESEARCH MONOGRAPH · KDC-MN-324

2-Arachidonoylglycerol (2-AG)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

79/100

The other endocannabinoid, actually more abundant than anandamide, similar caveats for in vivo work

2-AG is the endocannabinoid that anandamide gets all the press for despite 2-AG being roughly 100-200x more abundant in brain tissue. Sugiura and Mechoulam, plus Stella and colleagues, did the foundational work in the mid-90s showing it's a high-efficacy full agonist at both CB1 and CB2, in contrast to anandamide's partial-agonist profile. Thats a meaningful pharmacological difference and it matters for which endogenous tone dominates which downstream signaling.

The biosynthetic pathway runs through DAGL (diacylglycerol lipase) and the degradation is primarily MAGL (monoacylglycerol lipase) for somewhere around 85% of brain hydrolysis, with FAAH and ABHD6/12 picking up the rest. This is why MAGL inhibitors (JZL184, KML29) became such an attractive research class and why the in vivo phenotype of MAGL inhibition looks somewhat different from FAAH inhibition: you're elevating 2-AG, not anandamide, and you get more THC-like behavioral effects at high inhibition.

Mechanism is clean and well-mapped. The Sugiura papers, the Stella work, the Piomelli lab output, plus more recent contributions from Cravatt's group on the activity-based protein profiling side. The endocannabinoid biology textbook chapter is honestly one of the better-told receptor stories.

For research the same in vivo caveat as anandamide applies, but worse. 2-AG has even faster degradation kinetics because MAGL is highly active and ubiquitous. Direct systemic administration is essentially useless unless you co-administer a MAGL inhibitor. For in vitro and ex vivo work it's irreplaceable.

Sourcing: synthetic 2-AG (and the more stable 1-AG isomer that interconverts) is available from cannabinoid suppliers, purity by HPLC, NMR confirmation recommended. Stability is poor: oxidation of the arachidonoyl chain is the main issue, store at minus 80 under argon, dont leave thawed aliquots out. Cost is comparable to anandamide.

What we like: high-efficacy reference ligand for both CB1 and CB2, the abundance and DAGL/MAGL pathway gives you well-defined hooks for genetic and pharmacological manipulation, foundational for any serious endocannabinoid work.

What we dont like: the storage and stability issues make daily lab use a hassle, and the isomerization between 1-AG and 2-AG complicates quantitation.

Foundational pharmacology tool. If you're doing endocannabinoid biology you have this on hand.

Evidence: 88
Mechanism: 92
Reliability: 85
Safety: 80
Sourcing: 78
Value: 60
Signal: 65
Staying power: 88

Plain-language summary Intrigue 68 / 100

2-AG is the other major endocannabinoid alongside anandamide, and the higher-abundance one in brain tissue. Unlike anandamide it is a full agonist at both CB1 and CB2 receptors, meaning it produces the maximal possible signaling response, and it is built on demand from diacylglycerol in response to neuronal calcium influx. Its main job is retrograde synaptic signaling, where the receiving neuron sends 2-AG backward to dampen further input from the sending neuron. The breakdown enzyme MAGL has become a drug development target because blocking it raises endogenous 2-AG without giving cannabinoids directly. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endocannabinoid (monoacylglycerol)

A monoacylglycerol endocannabinoid; the principal full agonist at CB1 and CB2 receptors and the higher-abundance endocannabinoid in brain.

Abstract

2-Arachidonoylglycerol (2-AG; CAS 53847-30-6; molecular formula C23H38O4; molecular weight 378.55) is a monoacylglycerol endocannabinoid identified by Mechoulam and Sugiura groups in 1995. The compound is a full agonist at both CB1 and CB2 receptors, with higher concentrations in brain than anandamide. Synthesis is calcium-dependent via diacylglycerol lipase (DAGL); degradation is via monoacylglycerol lipase (MAGL) producing arachidonic acid and glycerol. The on-demand synthesis-degradation kinetics produce phasic retrograde signaling, particularly at synapses where 2-AG mediates short-term and long-term presynaptic depression. Plasma half-life is short (minutes) owing to MAGL-mediated degradation. Used as the canonical full-agonist endocannabinoid in neuroscience research; pharmacological elevation is achieved via MAGL inhibitors (JZL184, KML29). The 2-AG signaling pathway is central to retrograde synaptic communication and is the primary mechanism for endocannabinoid-mediated neuroplasticity.

Mechanism of action

Endogenous full agonist at CB1 and CB2 receptors. Calcium-dependent synthesis via DAGL; degradation via MAGL. Mediates retrograde synaptic signaling.

Reported research dose ranges

Research substrate; not used clinically owing to short half-life.

References

Mechoulam R, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995.
Sugiura T, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995.
Kano M, et al. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-324

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

2-Arachidonoylglycerol (2-AG)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs